[
THE INVESTOR] Biopharmaceutical company
Celltrion announced on Aug. 30 that its biosimilar Remsima has been prescribed for more than 105,000 patients in Europe by end-June since its launch in August 2013.
As the number of European patients who were prescribed Janssen’s Remicade (infliximab), the original drug to treat rheumatoid arthritis and autoimmune diseases, is estimated to be about 260,000, the biosimilar version is taking up about 40 percent of its market share, according to the company.
By Hwang You-mee (
glamazon@heraldcorp.com)
